Cargando…
Thiopurines Activate an Antiviral Unfolded Protein Response That Blocks Influenza A Virus Glycoprotein Accumulation
Influenza A viruses (IAVs) utilize host shutoff mechanisms to limit antiviral gene expression and redirect translation machinery to the synthesis of viral proteins. Previously, we showed that IAV replication is sensitive to protein synthesis inhibitors that block translation initiation and induce th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139708/ https://www.ncbi.nlm.nih.gov/pubmed/33762409 http://dx.doi.org/10.1128/JVI.00453-21 |
_version_ | 1783696055904239616 |
---|---|
author | Slaine, Patrick D. Kleer, Mariel Duguay, Brett A. Pringle, Eric S. Kadijk, Eileigh Ying, Shan Balgi, Aruna Roberge, Michel McCormick, Craig Khaperskyy, Denys A. |
author_facet | Slaine, Patrick D. Kleer, Mariel Duguay, Brett A. Pringle, Eric S. Kadijk, Eileigh Ying, Shan Balgi, Aruna Roberge, Michel McCormick, Craig Khaperskyy, Denys A. |
author_sort | Slaine, Patrick D. |
collection | PubMed |
description | Influenza A viruses (IAVs) utilize host shutoff mechanisms to limit antiviral gene expression and redirect translation machinery to the synthesis of viral proteins. Previously, we showed that IAV replication is sensitive to protein synthesis inhibitors that block translation initiation and induce the formation of cytoplasmic condensates of untranslated messenger ribonucleoprotein complexes called stress granules (SGs). In this study, using an image-based high-content screen, we identified two thiopurines, 6-thioguanine (6-TG) and 6-thioguanosine (6-TGo), that triggered SG formation in IAV-infected cells and blocked IAV replication in a dose-dependent manner without eliciting SG formation in uninfected cells. 6-TG and 6-TGo selectively disrupted the synthesis and maturation of the IAV glycoproteins hemagglutinin (HA) and neuraminidase (NA) without affecting the levels of the viral RNAs that encode them. By contrast, these thiopurines had a minimal effect on other IAV proteins or global host protein synthesis. Disruption of IAV glycoprotein accumulation by 6-TG and 6-TGo correlated with the activation of the unfolded protein response (UPR) sensors activating transcription factor 6 (ATF6), inositol-requiring enzyme 1 (IRE1), and double-stranded RNA-activated protein kinase (PKR)-like endoplasmic reticulum (ER) kinase (PERK), leading to downstream UPR gene expression. Treatment of infected cells with the chemical chaperone 4-phenylbutyric acid diminished thiopurine-induced UPR activation and partially restored the processing and accumulation of HA and NA. By contrast, chemical inhibition of the integrated stress response downstream of PERK restored the accumulation of NA monomers but did not restore the processing of viral glycoproteins. Genetic deletion of PERK enhanced the antiviral effect of 6-TG without causing overt cytotoxicity, suggesting that while UPR activation correlates with diminished viral glycoprotein accumulation, PERK could limit the antiviral effects of drug-induced ER stress. Taken together, these data indicate that 6-TG and 6-TGo are effective host-targeted antivirals that trigger the UPR and selectively disrupt the accumulation of viral glycoproteins. IMPORTANCE Secreted and transmembrane proteins are synthesized in the endoplasmic reticulum (ER), where they are folded and modified prior to transport. Many viruses rely on the ER for the synthesis and processing of viral glycoproteins that will ultimately be incorporated into viral envelopes. Viral burden on the ER can trigger the unfolded protein response (UPR). Much remains to be learned about how viruses coopt the UPR to ensure efficient synthesis of viral glycoproteins. Here, we show that two FDA-approved thiopurine drugs, 6-TG and 6-TGo, induce the UPR, which represents a previously unrecognized effect of these drugs on cell physiology. This thiopurine-mediated UPR activation blocks influenza virus replication by impeding viral glycoprotein accumulation. Our findings suggest that 6-TG and 6-TGo may have broad antiviral effects against enveloped viruses that require precise tuning of the UPR to support viral glycoprotein synthesis. |
format | Online Article Text |
id | pubmed-8139708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-81397082021-06-14 Thiopurines Activate an Antiviral Unfolded Protein Response That Blocks Influenza A Virus Glycoprotein Accumulation Slaine, Patrick D. Kleer, Mariel Duguay, Brett A. Pringle, Eric S. Kadijk, Eileigh Ying, Shan Balgi, Aruna Roberge, Michel McCormick, Craig Khaperskyy, Denys A. J Virol Vaccines and Antiviral Agents Influenza A viruses (IAVs) utilize host shutoff mechanisms to limit antiviral gene expression and redirect translation machinery to the synthesis of viral proteins. Previously, we showed that IAV replication is sensitive to protein synthesis inhibitors that block translation initiation and induce the formation of cytoplasmic condensates of untranslated messenger ribonucleoprotein complexes called stress granules (SGs). In this study, using an image-based high-content screen, we identified two thiopurines, 6-thioguanine (6-TG) and 6-thioguanosine (6-TGo), that triggered SG formation in IAV-infected cells and blocked IAV replication in a dose-dependent manner without eliciting SG formation in uninfected cells. 6-TG and 6-TGo selectively disrupted the synthesis and maturation of the IAV glycoproteins hemagglutinin (HA) and neuraminidase (NA) without affecting the levels of the viral RNAs that encode them. By contrast, these thiopurines had a minimal effect on other IAV proteins or global host protein synthesis. Disruption of IAV glycoprotein accumulation by 6-TG and 6-TGo correlated with the activation of the unfolded protein response (UPR) sensors activating transcription factor 6 (ATF6), inositol-requiring enzyme 1 (IRE1), and double-stranded RNA-activated protein kinase (PKR)-like endoplasmic reticulum (ER) kinase (PERK), leading to downstream UPR gene expression. Treatment of infected cells with the chemical chaperone 4-phenylbutyric acid diminished thiopurine-induced UPR activation and partially restored the processing and accumulation of HA and NA. By contrast, chemical inhibition of the integrated stress response downstream of PERK restored the accumulation of NA monomers but did not restore the processing of viral glycoproteins. Genetic deletion of PERK enhanced the antiviral effect of 6-TG without causing overt cytotoxicity, suggesting that while UPR activation correlates with diminished viral glycoprotein accumulation, PERK could limit the antiviral effects of drug-induced ER stress. Taken together, these data indicate that 6-TG and 6-TGo are effective host-targeted antivirals that trigger the UPR and selectively disrupt the accumulation of viral glycoproteins. IMPORTANCE Secreted and transmembrane proteins are synthesized in the endoplasmic reticulum (ER), where they are folded and modified prior to transport. Many viruses rely on the ER for the synthesis and processing of viral glycoproteins that will ultimately be incorporated into viral envelopes. Viral burden on the ER can trigger the unfolded protein response (UPR). Much remains to be learned about how viruses coopt the UPR to ensure efficient synthesis of viral glycoproteins. Here, we show that two FDA-approved thiopurine drugs, 6-TG and 6-TGo, induce the UPR, which represents a previously unrecognized effect of these drugs on cell physiology. This thiopurine-mediated UPR activation blocks influenza virus replication by impeding viral glycoprotein accumulation. Our findings suggest that 6-TG and 6-TGo may have broad antiviral effects against enveloped viruses that require precise tuning of the UPR to support viral glycoprotein synthesis. American Society for Microbiology 2021-05-10 /pmc/articles/PMC8139708/ /pubmed/33762409 http://dx.doi.org/10.1128/JVI.00453-21 Text en Copyright © 2021 Slaine et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Vaccines and Antiviral Agents Slaine, Patrick D. Kleer, Mariel Duguay, Brett A. Pringle, Eric S. Kadijk, Eileigh Ying, Shan Balgi, Aruna Roberge, Michel McCormick, Craig Khaperskyy, Denys A. Thiopurines Activate an Antiviral Unfolded Protein Response That Blocks Influenza A Virus Glycoprotein Accumulation |
title | Thiopurines Activate an Antiviral Unfolded Protein Response That Blocks Influenza A Virus Glycoprotein Accumulation |
title_full | Thiopurines Activate an Antiviral Unfolded Protein Response That Blocks Influenza A Virus Glycoprotein Accumulation |
title_fullStr | Thiopurines Activate an Antiviral Unfolded Protein Response That Blocks Influenza A Virus Glycoprotein Accumulation |
title_full_unstemmed | Thiopurines Activate an Antiviral Unfolded Protein Response That Blocks Influenza A Virus Glycoprotein Accumulation |
title_short | Thiopurines Activate an Antiviral Unfolded Protein Response That Blocks Influenza A Virus Glycoprotein Accumulation |
title_sort | thiopurines activate an antiviral unfolded protein response that blocks influenza a virus glycoprotein accumulation |
topic | Vaccines and Antiviral Agents |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139708/ https://www.ncbi.nlm.nih.gov/pubmed/33762409 http://dx.doi.org/10.1128/JVI.00453-21 |
work_keys_str_mv | AT slainepatrickd thiopurinesactivateanantiviralunfoldedproteinresponsethatblocksinfluenzaavirusglycoproteinaccumulation AT kleermariel thiopurinesactivateanantiviralunfoldedproteinresponsethatblocksinfluenzaavirusglycoproteinaccumulation AT duguaybretta thiopurinesactivateanantiviralunfoldedproteinresponsethatblocksinfluenzaavirusglycoproteinaccumulation AT pringleerics thiopurinesactivateanantiviralunfoldedproteinresponsethatblocksinfluenzaavirusglycoproteinaccumulation AT kadijkeileigh thiopurinesactivateanantiviralunfoldedproteinresponsethatblocksinfluenzaavirusglycoproteinaccumulation AT yingshan thiopurinesactivateanantiviralunfoldedproteinresponsethatblocksinfluenzaavirusglycoproteinaccumulation AT balgiaruna thiopurinesactivateanantiviralunfoldedproteinresponsethatblocksinfluenzaavirusglycoproteinaccumulation AT robergemichel thiopurinesactivateanantiviralunfoldedproteinresponsethatblocksinfluenzaavirusglycoproteinaccumulation AT mccormickcraig thiopurinesactivateanantiviralunfoldedproteinresponsethatblocksinfluenzaavirusglycoproteinaccumulation AT khaperskyydenysa thiopurinesactivateanantiviralunfoldedproteinresponsethatblocksinfluenzaavirusglycoproteinaccumulation |